August 28, 2010
Venue: ESC Congress – Stockholm / Sweden, 28 Aug 2010, 12.00-13.30
Course Director: Prof. Karl Swedberg
CME Provider: The Sahlgrenska Academy – University of Gothenburg in collaboration with A+ Science
Educational objectives
- To demonstrate that type 2 diabetes is an important risk factor for cardiovascular disease (CVD), and is very prevalent in patients with coronary artery disease (CAD)
- To provide an overview of recent trials of interventions to reduce CVD risk in type 2 diabetes patients and consider the implications of their findings for future management strategies
- To evaluate the current guidelines for the management of CAD patients with diabetes, and identify potential novel targets for therapy in this high-risk patient group
- To determine whether dual PPAR/PPAR agonism is an appropriate potential therapeutic strategy to address the multiple metabolic risk factors in CAD patients with type 2 diabetes and reduce their risk of recurrent CV events.
Determination of educational needs
The session will consider the need for novel therapies to address the multiple cardiovascular (CV) risk factors in patients with diabetes. The high prevalence of type 2 diabetes in patients with coronary artery disease (CAD, and their poorer long-term outcomes compared with non-diabetic patients will be highlighted. Current guidelines for the management of diabetic patients with CAD will be reviewed, and the implications of recent clinical trials of interventions to improve metabolic control in this population will be considered. Peroxisome proliferator-activated receptor (PPAR) agonists improve dyslipidaemia, while PPAR agonists reduce insulin resistance and also have beneficial effects on lipids and inflammation.
A combination of PPAR/PPAR agonism could address many of the metabolic abnormalities seen in type 2 diabetes, and the rationale for dual PPAR agonism in CAD patients with diabetes will be discussed. The educational needs were determined by review of recent published literature plus consultation with the esteemed chairmen and faculty.
Target audience: Trained cardiologists, Diabetologists, Lipidologists, Research Scientists and other physicians
Return to eventlist